Posts by: Ashraf Malhas, PhD

News

A study finds that, contrary to some reports, the use of inhaled nitric oxide can be effective in treating premature infants with acute pulmonary hypertension. The study, “The efficacy ... Read more

April 23, 2018April 23, 2018

Supplemental Oxygen Use Has Positive Effects in PAH Patients, Study Shows

News, PAH News

Supplemental oxygen use is associated with improved survival in a subpopulation of patients with pulmonary arterial hypertension (PAH), a study has found. Current guidelines that recommend oxygen supplementation therapy ... Read more

March 7, 2018March 7, 2018

PAH Patients’ Heathcare Costs Are Similar Before and After Treatment Starts, Study Shows

News, PAH News

The healthcare costs of Americans with pulmonary arterial hypertension (PAH) are about the same before and after treatment starts, mainly because high treatment costs offset fewer hospitalizations, a study shows. ... Read more

November 8, 2017November 8, 2017

Generic Molecule That Activates Mitochondrial Protein Seen to Treat PAH in Small Study

News

A generic molecule that works by activating a mitochrondrial protein, dichloroacetate (DCA), was seen in a Phase 1 clinical trial to reduce pulmonary arterial blood pressure and improve lung function ... Read more

October 4, 2017October 4, 2017

Japanese Study Links Main Pulmonary Artery Dilation with Worse Outcomes in Pediatric PAH

News, PAH News

Pulmonary artery dilation speeds up the progression of pediatric idiopathic and heritable pulmonary arterial hypertension (PAH), a Japanese study shows. Dilation of the main pulmonary artery (MPA) and narrowing of the ... Read more

September 15, 2017September 15, 2017

Study Examines Risk Factors Between Pulmonary Arterial Hypertension and SLE

News, PAH News

Pulmonary arterial hypertension (PAH) is a rare complication of systemic lupus erythematosus (SLE) and is associated with the presence of specific autoantibodies, a study has found. PAH is a complex ... Read more

September 5, 2017September 5, 2017

FDA Declines SteadyMed’s New Drug Application for Trevyent, Delivered via PatchPump, to Treat PAH

News, PAH News

The U.S. Food and Drug Administration (FDA) has declined SteadyMed Therapeutics‘ new drug application (NDA) for its Trevyent (treprostinil injection) therapy to treat pulmonary arterial hypertension (PAH). SteadyMed, with offices in San Ramon, California, ... Read more